A 56-year-old man with a germline BRCA2 mutation (S1982Rfs*22, exon 11) was found to have a prostate-specific antigen (PSA) of 32 ng/ml and subsequently diagnosed with Gleason 9 (5 + 4) prostate adenocarcinoma metastatic to the bone and lymph nodes29. This evidence concerns the gene BRCA2 and prostate adenocarcinoma.